Regeneron (REGN) Announces Positive Data on Oncology Candidate
REGNRegeneron(REGN) zacks.com·2024-05-24 22:31

Regeneron Pharmaceuticals, Inc. (REGN) announced positive new results from an ongoing phase I/II study on pipeline candidate REGN7075.The phase I/II first-in-human, open-label study is evaluating REGN7075, in combination with oncology drug Libtayo (cemiplimab). The study is currently enrolling patients with metastatic and locally advanced solid tumors who have exhausted standard treatment options.The trial includes an ongoing phase I dose-escalation portion and a phase II dose-expansion period. Patients fir ...